GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lattice Biologics Ltd (OTCPK:LBLTF) » Definitions » Asset Turnover

Lattice Biologics (Lattice Biologics) Asset Turnover : 0.00 (As of Jun. 2021)


View and export this data going back to 2001. Start your Free Trial

What is Lattice Biologics Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Lattice Biologics's Revenue for the three months ended in Jun. 2021 was $0.00 Mil. Lattice Biologics's Total Assets for the quarter that ended in Jun. 2021 was $0.62 Mil. Therefore, Lattice Biologics's Asset Turnover for the quarter that ended in Jun. 2021 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Lattice Biologics's annualized ROE % for the quarter that ended in Jun. 2021 was 13.94%. It is also linked to ROA % through Du Pont Formula. Lattice Biologics's annualized ROA % for the quarter that ended in Jun. 2021 was -16.80%.


Lattice Biologics Asset Turnover Historical Data

The historical data trend for Lattice Biologics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lattice Biologics Asset Turnover Chart

Lattice Biologics Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Sep16 Sep17 Sep18 Sep19 Sep20
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.63 0.68 0.36 0.82 0.93

Lattice Biologics Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 0.29 0.16 0.17 -

Competitive Comparison of Lattice Biologics's Asset Turnover

For the Medical Devices subindustry, Lattice Biologics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lattice Biologics's Asset Turnover Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lattice Biologics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Lattice Biologics's Asset Turnover falls into.



Lattice Biologics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Lattice Biologics's Asset Turnover for the fiscal year that ended in Sep. 2020 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Sep. 2020 )/( (Total Assets (A: Sep. 2019 )+Total Assets (A: Sep. 2020 ))/ count )
=2.464/( (2.275+3.018)/ 2 )
=2.464/2.6465
=0.93

Lattice Biologics's Asset Turnover for the quarter that ended in Jun. 2021 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Jun. 2021 )/( (Total Assets (Q: Mar. 2021 )+Total Assets (Q: Jun. 2021 ))/ count )
=0/( (0.632+0.606)/ 2 )
=0/0.619
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Lattice Biologics  (OTCPK:LBLTF) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Lattice Biologics's annulized ROE % for the quarter that ended in Jun. 2021 is

ROE %**(Q: Jun. 2021 )
=Net Income/Total Stockholders Equity
=-0.104/-0.746
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-0.104 / 0)*(0 / 0.619)*(0.619/ -0.746)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*-0.8298
=ROA %*Equity Multiplier
=-16.80 %*-0.8298
=13.94 %

Note: The Net Income data used here is four times the quarterly (Jun. 2021) net income data. The Revenue data used here is four times the quarterly (Jun. 2021) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Lattice Biologics's annulized ROA % for the quarter that ended in Jun. 2021 is

ROA %(Q: Jun. 2021 )
=Net Income/Total Assets
=-0.104/0.619
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-0.104 / 0)*(0 / 0.619)
=Net Margin %*Asset Turnover
= %*0
=-16.80 %

Note: The Net Income data used here is four times the quarterly (Jun. 2021) net income data. The Revenue data used here is four times the quarterly (Jun. 2021) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Lattice Biologics Asset Turnover Related Terms

Thank you for viewing the detailed overview of Lattice Biologics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Lattice Biologics (Lattice Biologics) Business Description

Traded in Other Exchanges
N/A
Address
512 East Madison Avenue, Suite A1, Belgrade, MT, USA, 59714
Lattice Biologics Ltd is a biologic product manufacturing company. It manufactures and markets biologic products to domestic and international markets. The products of the company include ADM dermis, DBM Putty, Bone scaffold, and Others, of which key revenue is derived from Bone scaffold. The biologic products are used in various applications such as enhancing fusion in spine surgery, enhancing breast reconstruction post mastectomy for breast cancer patients, sports medicine applications, promotion of bone in foot and ankle surgery, promotion of skull healing following neurosurgery, and subchondral bone defect repair in knee and other joint surgeries. The company generates its revenue from operations principally carried in the United States of America.

Lattice Biologics (Lattice Biologics) Headlines

No Headlines